Record · corpus.blog/posts/01a0f576-b8a4-72cc-b1d6-42a554e504ee
Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs · published 30 September 2026 · 2 min read
A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.
0blogs citing
- First cited
- —
- Most recent
- —
- Rank this month
- not ranked
- External links
- 0
- Words captured
- 286
Cited by
No blog we hold has cited this post yet.
Similar posts
Conception Grows First Early Human Eggs From Stem Cells
disabled-world.com
5 Jul 2026
Does CAR T-Cell Cancer Therapy Affect Fertility? A New Study Is Looking for Answers
cancerresearch.org
15 Sept 2026
Dene’s story: helping the future of cancer treatment
guysandstthomas.nhs.uk
1 Oct 2026
Links from this post
This post doesn't link to any pages we've captured.
Something wrong here? Report a problem
A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 8 October 2026).